These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37655416)

  • 1. [Cerebrolysin Treatment Reduces the Risk of Mild Cognitive Decline to Dementia in 1st-Degree Relatives of Alzheimer's Patients: A Prospective Comparative Study].
    Selezneva ND; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(8):90-97. PubMed ID: 37655416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first degree relatives of patients with Alzheimer's disease: the role of the ApoE genotype].
    Selezneva ND; Gavrilova SI; Kolykhalov IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(10. Vyp. 2):31-38. PubMed ID: 33205928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention of progression of cognitive decline in the first-degree relatives of patients with Alzheimer's disease].
    Selezneva ND; Roshchina IF; Korovaitseva GI; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(10):30-36. PubMed ID: 30499493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Citicoline in the treatment of cognitive impairment in first-degree relatives of AD patients: the influence of the ApoE genotype].
    Selezneva ND; Gavrilova SI; Roshchina IF; Ponomareva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(10. Vyp. 2):30-36. PubMed ID: 34870911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild Cognitive Impairment: a three-year prospective comparative study].
    Ponomareva EV; Androsova LV; Krinsky SA; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(4. Vyp. 2):92-99. PubMed ID: 38696157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic monitoring and prediction of the efficacy of neurotrophic treatment in patients with amnestic type of mild cognitive impairment].
    Gavrilova SI; Volpina OM; Kolykhalov IV; Fedorova YB; Selezneva ND; Ponomareva EV; Koroev DO; Kamynina AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(8):27-38. PubMed ID: 28884714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The therapeutic potential of cerebrolysin in the preventive therapy of Alzheimer's disease].
    Gavrilova SI; Fedorova IaB; Kolykhalov IV; Odinak MM; Emelin AIu; Kashin AV; Selezneva ND; Kalyn IaB; Roshchina IF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(8):24-8. PubMed ID: 18833104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrolysin for vascular dementia.
    Cui S; Chen N; Yang M; Guo J; Zhou M; Zhu C; He L
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31710397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Two-Year Observational Study to Evaluate Conversion Rates from High- and Low-Risk Patients with Amnestic Mild Cognitive Impairment to Probable Alzheimer's Disease in a Real-World Setting.
    Jang H; Na DL; Kwon JC; Jung NY; Moon Y; Lee JS; Park KW; Lee AY; Cho H; Lee JH; Kim BC; Park KH; Lee BC; Choi H; Kim J; Park MY
    J Alzheimers Dis Rep; 2024; 8(1):851-862. PubMed ID: 38910942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Systemic inflammatory markers in age-associated cognitive impairment and Alzheimer's disease].
    Kliushnik TP; Androsova LV; Mikhaylova NM; Kolykhalov IV; Zozulya SA; Dupin AM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(7):74-79. PubMed ID: 28805765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
    Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H
    J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Serum miR-206 Level Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer's Disease: A 5-Year Follow-up Study.
    Xie B; Liu Z; Jiang L; Liu W; Song M; Zhang Q; Zhang R; Cui D; Wang X; Xu S
    J Alzheimers Dis; 2017; 55(2):509-520. PubMed ID: 27662297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use.
    Gavrilova SI; Alvarez A
    Med Res Rev; 2021 Sep; 41(5):2775-2803. PubMed ID: 32808294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Possibilities of preventive treatment of Alzheimer's disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment].
    Gavrilova SI; Kolykhalov IV; Fedorova IaB; Selezneva ND; Kalyn IaB; Roshchina IF; Odinak MM; Emelin AIu; Kashin AV; Gustov AV; Antipenko EA; Korshunova IuA; Davydova TA; Messler G
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(1):62-9. PubMed ID: 20436440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study.
    Chen CC; Wei ST; Tsaia SC; Chen XX; Cho DY
    Br J Neurosurg; 2013 Dec; 27(6):803-7. PubMed ID: 23656173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological approaches to the therapy of Alzheimer's disease].
    Gavrilova SI
    Vestn Ross Akad Med Nauk; 2006; (9-10):30-4. PubMed ID: 17111921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin.
    Alvarez XA; Cacabelos R; Sampedro C; Aleixandre M; Linares C; Granizo E; Doppler E; Moessler H
    Eur J Neurol; 2011 Jan; 18(1):59-68. PubMed ID: 20500802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort.
    Liu P; Wu L; Peng G; Han Y; Tang R; Ge J; Zhang L; Jia L; Yue S; Zhou K; Li L; Luo B; Wang B
    Brain Behav Immun; 2019 Aug; 80():633-643. PubMed ID: 31063846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.
    Guekht AB; Moessler H; Novak PH; Gusev EI;
    J Stroke Cerebrovasc Dis; 2011; 20(4):310-8. PubMed ID: 20656516
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.